Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment

Introduction: The structured Benefit–risk Action Team (BRAT) approach aims to assist healthcare decision makers in treatment assessments. We applied BRAT to compare the benefit–risk profile of ranibizumab 0.5 mg versus laser photocoagulation for the treatment of diabetic macular oedema (DMO). Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Focke, Cruess, Alan, Dunger-Baldauf, Cornelia, Margaron, Philippe, Snow, Howard, Strain, William David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2017
Materias:
Diabetic Macular Oedema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813472/
https://www.ncbi.nlm.nih.gov/pubmed/29632615
http://dx.doi.org/10.17925/EE.2017.13.02.91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813472/
https://www.ncbi.nlm.nih.gov/pubmed/29632615
http://dx.doi.org/10.17925/EE.2017.13.02.91

Ejemplares similares